Contract drugmaker Catalent shows signs of recovery in Q1 revenue beat
(Reuters) -Catalent beat Wall Street's estimates for first-quarter revenue on Wednesday, as the contract drug manufacturer showed signs of improvement
2023-11-15 21:52
Catalent delays quarterly filing with SEC on $700 million impairment charge
Catalent will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of
2023-11-14 22:59